REYATAZ / ritonavir frarådes, med mindre det vurderes, at fordel/ risiko- forholdet for patienten berettiger brug af voriconazol (se pkt.
not recommended unless an assessment of the benefit/ risk to the patient justifies the use of voriconazole (see section 4.4).